Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Cerebrovascular accident, Chest pain, Inappropriate schedule of product administration, Incorrect route of product administration, Thrombosis
Clinical narrative: stroke; chest pain; blood clot; Tremors in left arm and hand; Incorrect route of product administration; first dose on 26 March 2021 and her second dose on 14 May 2021 with 49 days; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of THROMBOSIS (blood clot), CEREBROVASCULAR ACCIDENT (stroke), TREMOR (Tremors in left arm and hand) and CHEST PAIN (chest pain) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017B21A and 003A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma, Hashimoto's thyroiditis, Egg allergy, Latex allergy, Drug allergy (Morphine) and Drug allergy (hydrocodone).   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Cutaneous) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Cutaneous) dosage was changed to 1 dosage form. On 14-May-2021, the patient experienced INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Incorrect route of product administration) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose on 26 March 2021 and her second dose on 14 May 2021 with 49 days). In May 2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced TREMOR (Tremors in left arm and hand) (seriousness criterion hospitalization). On 05-Jul-2021, the patient experienced THROMBOSIS (blood clot) (seriousness criteria hospitalization and medically significant). On an unknown date, the patient experienced CEREBROVASCULAR ACCIDENT (stroke) (seriousness criteria hospitalization and medically significant) and CHEST PAIN (chest pain) (seriousness criterion hospitalization). On 14-May-2021, INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Incorrect route of product administration) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose on 26 March 2021 and her second dose on 14 May 2021 with 49 days) had resolved. On 07-Jul-2021, THROMBOSIS (blood clot) was resolving. At the time of the report, CEREBROVASCULAR ACCIDENT (stroke), TREMOR (Tremors in left arm and hand) and CHEST PAIN (chest pain) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Cutaneous), the reporter did not provide any causality assessments.   No family or personal history of high blood pressure, stroke, blood clotting. No blood tests came back for any clotting disease. No concomitant medication provided. No treatment information mentioned.  This is a case report of a 22-year-old, female who experienced adverse events of thrombosis, cerebrovascular accident, tremor, chest pain, incorrect route of product administration and inappropriate schedule of product administration. The patient was given a cutaneous route (the correct route is intramuscular injection) of Covid-19/mRNA-1273 vaccine with the lot numbers: 003A21A and 017B21A with the dosage interval of 49 days, first dose given 26 March 2021 and second dose given 14 May 2021 (the correct dosage interval is 25-35 days).  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.; Sender's Comments: This is a case report of a 22-year-old, female who experienced adverse events of thrombosis, cerebrovascular accident, tremor, chest pain, incorrect route of product administration and inappropriate schedule of product administration. The patient was given a cutaneous route (the correct route is intramuscular injection) of Covid-19/mRNA-1273 vaccine with the lot numbers: 003A21A and 017B21A with the dosage interval of 49 days, first dose given 26 March 2021 and second dose given 14 May 2021 (the correct dosage interval is 25-35 days).  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.